Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

Chronic cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia. Previous therapeutic modalities, including alkylating cytostatics, interferon and prednisolone, have been disappointing. However, several case reports and small-scaled studies have demonstrated promising results after...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 2006-02, Vol.47 (2), p.253-260
Hauptverfasser:	Schöllkopf, Claudia, Kjeldsen, Lars, Bjerrum, Ole Weiss, Mourits-Andersen, Hans Torben, Nielsen, Johan Lanng, Christensen, Bjarne Egelund, Jensen, Bjarne Anker, Pedersen, Bjarne Bach, Taaning, Ellen Birkerod, Klausen, Tobias Wirenfeldt, Birgens, Henrik
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anemia, Hemolytic, Autoimmune - drug therapy Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Autoimmune hemolytic anemia chronic cold agglutinin disease Chronic Disease Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies Humans Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Male Middle Aged phase II study Prospective Studies Recurrence Remission Induction Rituximab treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!